CDH17xCD3 bispecific T-cell engager
/ GemPharmatech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Novel T cell engager targeting CD3 and CDH17 for the treatment of solid tumors
(AACR 2026)
- "The novel CDH17xCD3 bispecific T-cell engager exhibits potent and targeted anti-tumor activity, supporting its translational potential as an immunotherapeutic agent for CDH17-positive solid tumors. The favorable efficacy and safety profile observed warrants further clinical investigation."
IO biomarker • Gastric Cancer • Hematological Malignancies • Oncology • Solid Tumor • CD69 • CDH17 • IL2RA
1 to 1
Of
1
Go to page
1